Enanta Pharmaceuticals
ENTA
108 hedge funds and large institutions have $391M invested in Enanta Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 51 reducing their positions, and 14 closing their positions.
108% more capital invested
Capital invested by funds: $188M → $391M (+$203M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
30% more call options, than puts
Call options by funds: $164K | Put options by funds: $126K
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
10.82% more ownership
Funds ownership: 95.09% → 105.91% (+11%)
2% more funds holding
Funds holding: 106 → 108 (+2)
49% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$12.6M |
| 2 |
Morgan Stanley
New York
|
+$11.5M |
| 3 |
CP
Caligan Partners
New York
|
+$11.4M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.68M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$6.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$11M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.85M |
| 3 |
Goldman Sachs
New York
|
-$1.27M |
| 4 |
BlackRock
New York
|
-$1.27M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.24M |
ENTA Hedge Fund Activity: Q1 2024 in Review
108 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2024, worth a combined $391M — up 108% from $188M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ENTA positions and 14 closed out — a net gain of 2 holders — while 26 added to existing stakes and 51 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $12.6M. The largest seller was Armistice Capital, cutting an estimated $11M.
- 108 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2024, up from 106 in Q4 2023.
- Funds reported $391M of Enanta Pharmaceuticals stock for Q1 2024, up 108% quarter-over-quarter.
- 16 funds opened new Enanta Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +2 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2024 was Marshall Wace, an estimated $12.6M added.
- The largest Enanta Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $11M sold.
Based on aggregated 13F filings for Q1 2024.